Aflibercept in persistent neovascular AMD: comparison of different treatment strategies in switching therapy.

Item

http://www.wikidata.org/entity/Q41765288

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Aflibercept in persistent neov ...... rategies in switching therapy.

@en

type

Item

label

Aflibercept in persistent neov ...... rategies in switching therapy.

@en

prefLabel

Aflibercept in persistent neov ...... rategies in switching therapy.

@en

P1476

Aflibercept in persistent neov ...... rategies in switching therapy.

@en

P2093

F Missiroli

http://www.w3.org/2001/XMLSchema#string

F Regine

http://www.w3.org/2001/XMLSchema#string

F Ricci

http://www.w3.org/2001/XMLSchema#string

M Parravano

http://www.w3.org/2001/XMLSchema#string

M Sciamanna

http://www.w3.org/2001/XMLSchema#string

M Tedeschi

http://www.w3.org/2001/XMLSchema#string

M Varano

http://www.w3.org/2001/XMLSchema#string

P2860

Ranibizumab for neovascular age-related macular degeneration

Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization.

Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD

A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interi

Visual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration.

Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial)

Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results.

Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors.

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration.

P2888

eye.2016.95

P304

1077-1083

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/EYE.2016.95

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1048677296

http://www.w3.org/2001/XMLSchema#string

P698

27229701

http://www.w3.org/2001/XMLSchema#string

P932

4985686

http://www.w3.org/2001/XMLSchema#string